<DOC>
	<DOCNO>NCT02218697</DOCNO>
	<brief_summary>The purpose study investigate immunogenicity safety GSK Biologicals ' influenza vaccine Influsplit™ Tetra ( Fluarix™ Tetra ) co-administered Merck &amp; Co. Inc. 's pneumococcal vaccine ( Pneumovax™23/Pneumovax ) adults 50 year age old risk complication influenza pneumococcal infection .</brief_summary>
	<brief_title>Evaluation Immunogenicity Safety GlaxoSmithKline ( GSK ) Biologicals ' Quadrivalent Influenza Vaccine Influsplit™ Tetra ( Fluarix™ Tetra ) ( GSK2321138A ) When Co-administered With Pneumovax™ 23 Adults 50 Years Age Older</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol ( e.g . completion diary card , return followup visit ) . A male female age 50 year time first vaccination risk complication influenza and/or pneumococcal infection , meet respective country ' recommendation vaccination influenza pneumococcal disease . At risk subject include adult chronic respiratory , heart , kidney , liver neurological disease ; human immunodeficiency virus ( HIV ) disease combination antiretroviral therapy ( cART ) cluster differentiation 4 ( CD4 ) Tcell count great 350 cells/mm3 ; sickle cell disease coeliac syndrome may lead splenic dysfunction ( asplenics exclude ) . The decision enrol base investigator clinical judgement . Written inform consent obtain subject . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Inhaled , topical lowdose intraarticular steroid allow . Planned administration/administration vaccine foreseen study protocol within period start 30 day first dose 30 day last dose vaccine . Administration vaccine document `` Concomitant vaccination '' electronic Case Report Form ( eCRF ) . Administration longacting immunemodifying drugs/treatment within six month prior first vaccine dose expect administration time study period . These immunosuppressant drugs/treatment/Biologics include : Methotrexate Leflunomide Azathioprine 6mercaptopurine Cyclosporin A Cyclophosphamide Tacrolimus , everolimus , sirolimus , temsirolimus Mycophenolate mofetil Antilymfocytaire immunoglobulins Tumor Necrosis Factor ( TNF ) inhibitor : Adalimumab ( Humira® ) , certolizumab ( Cimzia® ) , etanercept ( Enbrel® ) , golimumab ( Simponi® ) infliximab ( Remicade® ) Monoclonal antibody biologicals : Rituximab ( Mabthera® ) , Abatacept ( Orencia® ) , tocilizumab ( RoActemra® ) , basiliximab ( Simulect® ) , Natalizumab ( Tysabri® ) cluster differentiation 3 ( CD3 ) , … Antitumor agent : alkylating agent , antimetabolite , antitumor antibiotic , topoisomerase inhibitor , microtubule inhibitor antitumor agent Lenalidomide Revlimid® Tasonermin : Beromun® Proleukin® ( aldesleukin ; Novartis , … ) Tyrosine kinase inhibitor ( Glivec® ) Omalizumab Xolair® Eculizumab Soliris® The list compile : [ Federal Public Service Belgium : Health , Food Chain Safety Environment ] . Any immunosuppressive treatment opinion investigator allow adequate immune response . Inhaled , topical lowdose intraarticular steroid allow . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product . Previous vaccination pneumococcal vaccine within last five year . Previous vaccination influenza vaccine within last six month . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . HIV infected subject cART CD4 Tcell count 350 cells/mm3 enrol . History reaction hypersensitivity likely exacerbate component vaccine . Acute disease and/or fever time enrolment . Fever define temperature ≥ 38.0°C ( 100.4°F ) . The preferred route record temperature study axillary . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever [ ≥ 38.0°C ( 100.4°F ) ] may enrol discretion investigator . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution . Any condition , opinion investigator , prevents subject participate study would make intramuscular ( IM ) injection unsafe . Asplenia dysfunction spleen . This exclude homozygous sickle cell disease coeliac syndrome may lead splenic dysfunction . Acute clinically significant ( i.e . medically significant change baseline condition past 30 day ) pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . History chronic alcohol consumption and/or drug abuse . History GuillainBarré syndrome . A history anaphylaxis follow ANY vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Influsplit Tetra ( Fluarix Tetra ) 2014/2015 season</keyword>
	<keyword>Safety</keyword>
	<keyword>Adults</keyword>
	<keyword>Pneumovax 23/Pneumovax</keyword>
	<keyword>Co-administration</keyword>
	<keyword>Elderly</keyword>
	<keyword>Seasonal influenza</keyword>
	<keyword>Pneumococcal infection</keyword>
</DOC>